Madiha Derouazi PhD

Ms. Madiha Derouazi Founded Amal Therapeutics SA in 2012 and serves as its Chief Executive Officer. Ms. Derouazi has been working on Vector Engineering and Therapeutic Cancer Vaccines for over 9 years.

She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research, the so called bench-to-bedside. After several years working on recombinant protein production (upstream), she started developing different antigen delivery vectors. In the Laboratory of Tumor Immunology of the University of Geneva, she designed and characterized the CPP-based multi-epitopic cancer vaccine that is being progressed by Amal Therapeutics. Ms. Derouazi holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.